# TRYbeCA-1

Source: https://onco.cc/trials/trybeca-1/  
OnCo record `trybeca-1` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Eryaspase, an enzyme carried inside red blood cells, did not lengthen survival when added to second-line chemotherapy for pancreatic cancer.

## Summary

TRYbeCA-1 randomised patients with metastatic pancreatic adenocarcinoma progressing after first-line treatment to eryaspase plus gemcitabine and nab-paclitaxel or irinotecan-based chemotherapy, or chemotherapy alone. The primary endpoint of overall survival was not met when the trial reported in 2021.

## Fields

- Kind: Trial
- Status: negative
- Last checked: 2026-09-17
- Registry id: NCT03665441
- Phase: 3
- Setting: Second-line metastatic pancreatic adenocarcinoma: eryaspase with chemotherapy versus chemotherapy alone
- Sponsor: Erytech Pharma
- Result: Primary overall survival endpoint not met.
- Outcomes: Overall survival: Eryaspase + chemotherapy 7.5 months vs Chemotherapy alone 6.7 months, HR 0.92; Progression-free survival: Eryaspase + chemotherapy 3.7 months vs Chemotherapy alone 3.4 months, HR 0.88; Objective response rate: Eryaspase + chemotherapy 16.1% vs Chemotherapy alone 12.5%

## Sources

- ClinicalTrials.gov NCT03665441: https://clinicaltrials.gov/study/NCT03665441
- Hammel et al., Journal of Clinical Oncology 2025: TRYbeCA-1, eryaspase with chemotherapy as second-line treatment: https://doi.org/10.1200/JCO-25-00872

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Eryaspase](https://onco.cc/drugs/eryaspase/), [Gemcitabine + nab-paclitaxel](https://onco.cc/drugs/gemcitabine-nab-paclitaxel/)
- companies: [Phaxiam Therapeutics (formerly ERYtech Pharma)](https://onco.cc/companies/phaxiam/)
- key papers: [TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma](https://onco.cc/key-papers/paper-hammel-j-clin-oncol/)
- terms: [Pancreatic cancer: the failed and stopped programmes and why](https://onco.cc/terms/pancreatic-failed-programmes/)

---
JSON: https://onco.cc/api/v1/entities/trybeca-1.json